Rev. 05/27/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Benjamin P. Warner

Docket No.: S-94,661

Serial No.:

09/859,701

Examiner:

Filed

5/16/2001

Art Unit:

For

METHOD FOR DETECTING BINDING

EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY

RECEIVED

Mail Stop Sequence Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

MAR 1 0 2004

SUBMISSION OF SUBSTITUTE"SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

(check and complete this item, if applicable)

1.	\boxtimes	This replies to the Office Letter dated <u>12/30/2003</u> .
----	-------------	---

A copy of the Office Letter is enclosed.

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

☑ deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents, P. O. Box 1450,
Alexandria, VA 22313-1450.

FACSIMILE

☐ transmitted by facsimile to the United States Patent and Trademark Office.

Pate: + ebruary 17, 2004

Samuel L. Borkowsky

(type or print name of person certifying)

02/26/2004 HLE333

00000085 122150 0985970

01 FC:2251

55.00 DA

IDENTIFICATION OF PERSON MAKING STATEMENT

2.	I, Samuel L. Borkowsky						
	(type or print name of declarant signing below) state the following:						
2	Cubmit	ITEMS BEING SUBI	MITTED				
3.	Submiti	Submitted herewith is/are:					
	•	(check each item as applicable)					
	A. 🛚	"Sequence Listing(s)" for the nucleotide and application. Each "Sequence Listing" is assi C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 a	igned a separate identifier as required in 37				
	В. 🛚	An amendment to the description and/or clasequence by use of the assigned identifier,					
	c. 🛛	An amendment requesting entry of the Sequence	uence Listing into the specification.				
	D. 🛚	A copy of each "Sequence Listing" submittee form, in accordance with the requirements of	ed for this application in computer readable of 37 C.F.R. §§ 1.821(e) and 1.824.				
	E. 🗌	Please transfer to this application, in accord readable copy(ies) from applicant's other applicant applica	dance with 37 C.F.R. § 1.821(e), the computer oplication identified as follows:				
		In reapplication of:					
			roup No.: xaminer:				
		readable form(s) of applicant's other applicat of the application as follows:	ion corresponds to the "Sequence				
	mputer Read her application		"Sequence Identifier" (this application)				
E. A statement that the content of each "Sequence Listing" submitted and each comreadable copy are the same, as required in 37 C.F.R. § 1.821 (g).							
		Because the statement is not made by Office, the statement is verified as requ	a person registered to practice before the ired in 37 C.F.R. § 1.821(b).				
	F. 🛚	Because this submission is made in fulfilling a statement that the submission includes no	g the requirement under 37 C.F.R. § 1.821 (g), o new matter.				
		Because the statement is not made by Office, the statement is verified, as requ	a person registered to practice before the uired in 37 C.F.R. § 1.821(g).				

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4.	I hereby state: (complete applicable item A and/or B)						
	A. ⊠B. ⊠	requested to be "Sequence List All papers acco	transferred from applicating" to which it is indicate	on, or for which a request for transfer from			
5 A	: *	••	STATU				
5. Appl							
\boxtimes	claims s	mall entity status	3				
			EXTENSION (OF TIME			
6. The	proceed	dings herein are	for a patent application a	and the provisions of 37C.F.R. § 1.136 apply.			
(a) 🛚	a) Applicant petitions for an extension of time under 37 C.F.R. § 1.136 (fees: 37 C.F.R. § 1. 1 7(a)(l)-(4)) for the total number of months checked below:						
	Extensi (month		Fee for other than small entity	Fee for small entity			
	three	month months e months months	\$ 110.00 \$ 410.00 \$ 930.00 \$1,450.00	\$ 55.00 \$205.00 \$465.00 \$725.00			
			Fee:	\$ <u>55.00</u>			
If an ac	dditional	extension of time	e is required, please con	sider this a petition therefor.			
		(ch	eck and complete the ne	ext item, if applicable)			
An extension for months has already been secured. The fee paid therefor of \$ is deducted from the total fee due for the total months of extension now requested.							
			Extension	on fee due with this request \$			
			or				
(b) 🗌	Applicant believes that- no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.						
			FEE PAYN	IENT			
7.	Attache	ed is a check in the	he sum of				
\boxtimes			-2150 the sum of \$55.0	<u>0</u> .			

FEE DEFICIENCY

8. If any additional extension and/or fee is required, charge

Account No. 12-2150 .

SIGNATURE(s)

Respectfully submitted,

Date: February 17, 2004

Reg. No.: 42,346 Phone: (505) 665-3111 Signature of Agent

Samuel L. Borkowsky Los Alamos National Laboratory

LC/IP, MS A187

Los Alamos, New Mexico 87545


COMMISSIONER FOR PATENTS
COMMISSIONER FOR PATENTS
PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 2023
WWW.uspto.gov

APPLICATION NO. / CONTROL NO. 09/859,701

FILING DATE 5-16-01 FIRST NAMED INVENTOR / PATERALINATION Benjamin P. Warner

ATTORNEY DOCKET NO. 594.661

ally B



DATE MAILED: 12-30-03 RECEIVED

MAR 1 0 2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed March 27, 2003 is not fully responsive to the Office communication mailed February 20, 2003 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the reply appears to be <u>bona fide</u> attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of **ONE** (1) **MONTH** from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Counts, Art Unit 1641, whose telephone number is (703) 305-1444.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on (703) 305-3399.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

RECEIVED

Notice to Control Management

Application No. 09/859,701 MAR 1 0 2004 pjamin P. Warner

Examiner Art Unit Paper No 9

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

the	requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
×	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
Ø	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
×	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the same

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other:

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212

Patent Software Program Support

Technical Assistance......703-287-0200

To Purchase Patent Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY